Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study (Q30882161)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hisashi Yamanaka

13

object named as

Hisashi Yamanaka

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

author name string

Eiichi Tanaka

1

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Eisuke Inoue

2

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Daisuke Hoshi

3

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Yoko Shimizu

4

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Akiko Kobayashi

5

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Naoki Sugimoto

6

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Kumi Shidara

7

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Eri Sato

8

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Yohei Seto

9

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Ayako Nakajima

10

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Shigeki Momohara

11

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Atsuo Taniguchi

12

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

publication date

11 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Modern Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

503-513

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Quantifying the economic burden of productivity loss in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of t

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Therapies for active rheumatoid arthritis after methotrexate failure

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

[Economic evaluation of rheumathoid arthritis monotherapy with tocilizumab and adalimumab].

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.1001475

21 January 2018

Identifiers

10.3109/14397595.2014.1001475

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30882161&oldid=1568009792"